LL-37, the only human cathelicidin, is a multifunctional immune peptide that kills microbes, prevents sepsis, attracts immune cells, promotes healing, and is regulated by vitamin D.
Only 1 human cathelicidinWhile many animals produce multiple cathelicidins, humans rely on a single one — LL-37 — for an extraordinary range of immune functions.
What the researchers found
LL-37 — the only human cathelicidin antimicrobial peptide — does far more than kill bacteria. This review catalogs its many roles: it kills a broad range of microorganisms, neutralizes bacterial toxins (LPS) to prevent septic shock, attracts immune cells to infection sites, prevents neutrophil death, stimulates new blood vessel growth, promotes tissue repair, and triggers cytokine release. Its production is regulated by vitamin D (which explains the sun exposure-immunity connection), bacterial products, and oxygen levels. However, at inflamed sites, DNA and proteins from dead cells can neutralize LL-37, limiting its effectiveness.
Why it matters
LL-37 is the only cathelicidin peptide humans produce, making it uniquely important in our innate immune defense. Understanding its multiple functions — from direct microbial killing to wound healing to immune signaling — is essential for developing it as a therapeutic agent. The vitamin D connection also has public health implications, as vitamin D deficiency may impair LL-37 production and compromise immune defense.
How the study worked
This is a comprehensive review paper synthesizing published research on LL-37's antimicrobial activity, immunomodulatory functions, gene regulation, and potential therapeutic applications.
Who was studied
Review of published literature (no direct study population)
What this study cannot tell us
As a review paper, no new experimental data are presented. The therapeutic applications of LL-37 discussed were largely theoretical at the time of publication. The review may not capture more recent discoveries about LL-37's roles in autoimmune conditions and cancer.
How to read the evidence
This is moderate-strength evidence from a comprehensive review published in a peer-reviewed immunology journal. It synthesizes findings from numerous basic science and preclinical studies.
When this study was published
Published in 2010. LL-37 research has expanded enormously since, particularly regarding its roles in autoimmune diseases, cancer biology, and COVID-19 immunity. The core functions described here remain well-established.
The bigger picture
LL-37 sits at the center of innate immune defense and has become one of the most studied antimicrobial peptides in the world. Its connection to vitamin D has influenced public health recommendations, and synthetic versions are being explored as new antibiotics for drug-resistant infections. Understanding how LL-37's many functions work together — and what limits them — is key to developing peptide-based immunotherapies.
Questions still open
- Can synthetic LL-37 analogs be developed that retain antimicrobial activity but resist inactivation at inflamed sites?
- How much of vitamin D's immune-boosting reputation is specifically attributable to LL-37 production?
- Could LL-37 or its derivatives be used therapeutically to prevent sepsis in high-risk patients?
Common questions
What is LL-37 and where does your body make it?
Why is vitamin D important for LL-37 production?
Read the original research
Cathelicidin LL-37: a multitask antimicrobial peptide.
Archivum immunologiae et therapiae experimentalis, 58(1), 15-25
Citation
Bucki, Robert; Leszczyńska, Katarzyna; Namiot, Andrzej; Sokołowski, Wojciech. (2010). Cathelicidin LL-37: a multitask antimicrobial peptide.. Archivum immunologiae et therapiae experimentalis, 58(1), 15-25. https://doi.org/10.1007/s00005-009-0057-2